Industry

Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs

Vision Monday4d ago1 min read

ALISO VIEJO, Calif.—Alcon (SIX/NYSE: ALC), a global leader in eyecare, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on providing high-quality customized vision to patients following cataract surgery, have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). As part of the agreement, RxSight will receive a $60 million upfront payment to begin development and could receive up to an additional $140 million in payments as development and regulatory milestones are met, the announcement stated.

Read full article on Vision Monday

AI Summary

Quick Take

Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). The agreement includes a $60 million upfront payment to RxSight, with the potential for an additional $140 million in milestone-based payments as the technology moves through development and regulatory phases.

Why It Matters

This partnership signals a major move toward combining adjustable lens technology with presbyopia correction, addressing a significant hurdle in premium cataract surgery. While RxSight is known for its light-adjustable monofocal lenses, integrating this adjustability into PCIOLs could allow surgeons to fine-tune multifocal or extended depth of focus outcomes after the eye has healed. For Alcon, this collaboration strengthens its dominant position in the IOL market by potentially adding a highly customizable option to its presbyopia-correcting portfolio, which is currently a high-growth segment of refractive-cataract surgery.

Key Details

The collaboration is non-exclusive, allowing both companies flexibility in their broader business strategies.
RxSight receives an immediate $60 million upfront payment to begin the development of the adjustable PCIOL platform.
The deal structure includes up to $140 million in additional payments contingent upon reaching specific development and regulatory milestones.
The partnership focuses specifically on intraocular lenses designed to provide customized vision and presbyopia correction following cataract surgery.

Who's Affected

Cataract SurgeonsRefractive SurgeonsComprehensive OphthalmologistsPractice Owners

What's Next

Following the initial $60 million payment, development will commence on the new lens platform. Industry observers should watch for future announcements regarding clinical trial phases and regulatory submissions, which will trigger the remaining $140 million in milestone payments.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.